Clinical Features, Treatment, and Outcome of HIV-Associated Immune Thrombocytopenia in the HAART Era

Table 1

Clinical characteristics of 31 patients with HIV-associated ITP diagnosed since 1996.

Characteristic	𝑁
Age at ITP presentation (years)
≤40	12
>40	19
Gender
Male	25
Female	5
Transgender (MF)	1
Platelet count (×10^9/L)
≤10	15
>10	16
Hemoglobin at ITP diagnosis (g/L)
<90	4
>90	24
Clinical bleeding	17
Site of bleeding
Epistaxis	14
Menorrhagia	3
Gingival bleed	2
Gastrointestinal bleed	1
Hemoptysis	1
HIV risk factor (𝑁=26)
Sexual	10
IDU	16
CD4 at ITP diagnosis (cells/μL, 𝑁=29)
<200	8
≥200	21
Prior AIDS^1	5
Coinfections
Hepatitis B	4
Hepatitis C	12
Receiving HAART^2 at ITP diagnosis
No	20
Yes	10
Comorbidities	15

¹Mycobacterium avian complex, 𝑛=2; Pneumocystis jirovecii pneumonia,𝑛=2; anal condylomata, 𝑛=1.
²HAART was 1 nucleoside analog (NA), 1 protease inhibitor, and either a 2nd NA or a nonnucleoside reverse transcription inhibitor.